FDA Orange Book
Is there a generic for Rapivab?
Rapivab contains peramivir. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Rapivab (peramivir). The Orange Book shows its last listed patent expires May 7, 2027.
Run it in Rivvi
Map Rapivab and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Rapivab products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| solution, intravenous | 200MG/20ML (10MG/ML) | Marketed (Rx) | None | 0 | None |
NDA 206426, held by BIOCRYST PHARMACEUTICALS INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Rapivab patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 10391075 | February 12, 2027 | Method of use | U-2622 | 206426 |
| 10391075 | February 12, 2027 | Method of use | U-3069 | 206426 |
| 8778997 | May 7, 2027 | Method of use | U-2622 | 206426 |
| 8778997 | May 7, 2027 | Method of use | U-1627 | 206426 |
| 8778997 | May 7, 2027 | Method of use | U-3069 | 206426 |
Questions
Is there a generic for Rapivab?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Rapivab (peramivir). The Orange Book shows its last listed patent expires May 7, 2027.
What is the generic name for Rapivab?
The active ingredient in Rapivab is peramivir, per the FDA Orange Book.
When does the Rapivab patent expire?
The last patent listed for Rapivab in the Orange Book expires May 7, 2027. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.